8-K: BioSig Technologies Implements 1-for-10 Reverse Stock Split

BioSig Technologies has completed a 1-for-10 reverse stock split, effective February 1, 2024, to reduce the number of outstanding shares.

Summary

• BioSig Technologies has enacted a 1-for-10 reverse stock split of its common stock.
• The reverse stock split was approved by the company's stockholders at the annual meeting on December 18, 2023.
• The reverse stock split became effective at 4:05 p.m. New York time on February 1, 2024.
• Every ten shares of common stock were combined into one share.
• The number of outstanding shares decreased from 93,344,435 to approximately 9,334,636, subject to rounding up of fractional shares.
• The par value per share remains at $0.001.
• The number of authorized shares of common stock did not change.
• Adjustments were made to stock options, restricted stock units, warrants, and convertible preferred stock.
• The stock began trading on a split-adjusted basis on February 2, 2024, on the Nasdaq Capital Market under the symbol BSGM.
• The new CUSIP number for the common stock is 09073N300.

Sentiment

Score: 5

Explanation: The document is neutral in tone, detailing a corporate action. While a reverse stock split can be a sign of financial difficulty, it is a common practice and the document does not indicate any immediate negative implications.

Positives

• The reverse stock split was approved by stockholders, indicating shareholder support.
• The company has taken action to meet listing requirements of the Nasdaq Capital Market.

Negatives

• The reverse stock split reduces the number of outstanding shares, which can sometimes be perceived negatively by investors.

Risks

• The reverse stock split may have an effect on the price of BioSig's common stock.
• There is a risk that BioSig may not be able to maintain compliance with Nasdaq listing requirements.
• The company faces risks related to manufacturing, financing, competition, and regulatory approvals.
• Pandemics or worldwide health issues could impact the company's ability to conduct business and raise capital.

Future Outlook

The company will continue to trade on the Nasdaq Capital Market under the symbol BSGM. The company is subject to various risks and uncertainties that could affect future performance.

Management Comments

• The Board of Directors determined to effect the Reverse Stock Split at a ratio of 1-for-10.
• The reverse stock split will affect all stockholders uniformly.

Industry Context

Reverse stock splits are a common corporate action, often used by companies to increase their stock price and maintain listing compliance. This action is not uncommon in the medical technology sector.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies to regain compliance with exchange listing requirements, particularly when a stock price has fallen below a minimum threshold.
• Many companies in the biotech and medical device sectors have used reverse stock splits to maintain their listing on major exchanges such as Nasdaq.
• For example, companies like Aeterna Zentaris and Ocugen have recently undergone reverse stock splits to meet Nasdaq's minimum bid price requirement.
• The 1-for-10 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares which will be rounded up.
• The reverse stock split may impact the stock price, which could affect shareholder value.

Next Steps

• The company's stock will continue to trade on the Nasdaq Capital Market under the symbol BSGM.
• Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker.

Key Dates

Keywords

reverse stock split, common stock, stockholders, Nasdaq, BSGM, share consolidation, equity, corporate action